Global Co-development Deals in Pharma, Biotech & Diagnostics 2010-2015

Published: April 2015
No. of Pages: 1005
   

The Global Co-development Deals in Pharma, Biotech & Diagnostics 2010-2015 report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered into by the worlds leading life science companies.

The report provides a detailed understand and analysis of how and why companies enter co-development deals.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual co-development contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of co-development dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in co-development as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of co-development deals. The chapter includes numerous case studies to enable understanding of both pure co-development deals and multicomponent deals where co-development forms a part.

Chapter 4 provides a review of the leading co-development deals since 2010. Deals are listed by headline value, signed by big pharma and big biotech, most active big pharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapters 5 and 6 provide a comprehensive listing of the top 50 bigpharma and bigbiotech companies with a brief summary followed by a comprehensive listing of co-development contract deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of co-development deals signed and announced since 2010 where a contract document is available. The chapter is organized by A-Z, stage of development at signing, technologyand therapeutic area. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

The report also includes numerous table and figures that illustrate the trends and activities in co- development dealmaking since 2010.

In addition, a comprehensive appendix is provided organized by co-development partnering company A-Z , stage of development, therapeutic target, technology type and deal type definitions. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about co-development partnering in the research, development and commercialization of technologies and products.

Report scope

Global Co-development Deals in Pharma, Biotech & Diagnostics 2010-2015 is intended to provide the reader with an in-depth understanding of the co-development trends and structure of deals entered into by leading life science companies worldwide.

Global Co-development Deals in Pharma, Biotech & Diagnostics 2010-2015 includes:

  • Trends in co-development dealmaking in the biopharma industry since 2010
  • Analysis of co-development deal structure
  • Case studies of real-life co-development deals
  • Comprehensive listing of co-development deals since 2010
  • Access to co-development contract documents
  • Key financial benchmarks for headline, upfront, milestone and royalty rates
  • The leading co-development deals by value since 2010
  • Most active co-development dealmakers since 2010
  • The leading co-development partnering resources

In Global Co-development Deals in Pharma, Biotech & Diagnostics 2010-2015 available deals and contracts are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type

Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.

The Global Co-development Deals in Pharma, Biotech & Diagnostics 2010-2015 report provides comprehensive access to available contract documents for co-development deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How do milestone align with clinical stage development phases?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Co-development Deals in Pharma, Biotech & Diagnostics 2010-2015 provides the reader with the following key benefits:

  • In-depth understanding of co-development deal trends since 2010
  • Analysis of the structure of co-development agreements with numerous real life case studies
  • Comprehensive listing of all co-development deals since 2010, together with deal terms, value and press release
  • Comprehensive access to actual co-development contracts entered into by the world's life science companies
  • Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates
  • Insight into the terms included in a co-development agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Global Co-development Deals in Pharma, Biotech & Diagnostics 2010-2015

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in co-development dealmaking
2.1. Introduction
2.2. Definition of co-development deals
2.3. Success factors for co-development deals
2.4. When co-development can be useful
2.5. Attributes of co-development deals
2.6. Aligning partners to make the co-development work
2.7. Trends in co-development deals since 2010
2.8. Option to co-develop
2.9. The future of co-development deals

Chapter 3 - Overview of co-development deal structure
3.1. Introduction
3.2. Pure versus multi-component co-development deals
3.3. Pure co-development agreement structure
3.3.1. Example co-development agreements
3.3.1.a. Case study 1: Ambrx - Zhejiang Medicine - June 2013
3.3.1.b. Case study 2: UniQure - Chiesi - July 2013

Chapter 4 - Leading co-development deals
4.1. Introduction
4.2. Top co-development deals by value
4.3. Most active co-development dealmakers
4.4. Big pharma co-development deal activity
4.5. Big biotech co-development deal activity

Chapter 5 - Big pharma and big biotech co-development deals
5.1. Introduction
5.2. How to use co-development deals
5.3. Big pharma co-development agreement listings

Chapter 6 - Big biotech co-development deals
6.1. Introduction
6.2. How to use co-development deals
6.3. Big biotech co-development agreement listings

Chapter 7 - Co-development contract directory 2010-2015
7.1. Introduction
7.2. Company A-Z
7.3. By therapy area
7.4. By stage of development at signing
7.5. By technology area

Appendix
Appendix 1 - Co-development references
Appendix 2 - Resources
Appendix 3 - Deal type definitions
Appendix 4 - Co-development dealmaking - by companies A-Z
Appendix 5 - Co-development dealmaking - by stage of development
Appendix 6 - Co-development dealmaking - by therapeutic target
Appendix 7 - Co-development dealmaking - by technology type
About Wildwood Ventures
Current Partnering
Current Agreements
Order Form - Upgrades to subscription access products
Recent report titles from CurrentPartnering
Order Form - Reports

See separate appendix file for:
Appendix 1 - Co-development dealmaking - by financial disclosure
Appendix 2 - Co-development dealmaking - by companies A-Z
Appendix 3 - Co-development dealmaking - by stage of development
Appendix 4 - Co-development dealmaking - by therapeutic target
Appendix 5 - Co-development dealmaking - by technology type

List of Figures

Figure 1: Definition of co-development
Figure 2: Situations where co-development can prove useful
Figure 3: Key components of a co-development deal
Figure 4: Issues in implementing co-development agreements
Figure 5: Trends in co-development deal announcements, 2010-2015
Figure 6: Co-development deals signed at each phase of development, 2010-2015
Figure 7: Co-development agreements - what should a contract include?
Figure 8: Components of the co-development deal structure
Figure 9: Top co-development deals by value since 2010
Figure 10: Most active co-development dealmakers 2010-2015
Figure 11: Bigpharma - top 50 - Co-development deals 2010 to 2015
Figure 12: Big pharma co-development deal frequency - 2010 to 2015
Figure 13: Big biotech - top 50 - cancer vaccine deals 2010 to 2015
Figure 14: Big biotech cancer vaccine deal frequency - 2010 to 2015
Figure 15: Online partnering resources
Figure 16: Deal type definitions

Published By: Current Partnering
Product Code: Current Partnering147


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we’ll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest: